RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency

Gene Therapy

Volumn 18, Issue 4, 2011, Pages 372-383

  Wang, S T ^a   Chang, C C ^a,b   Yen, M C ^c   Tu, C F ^c   Chu, C L ^d   Peng, Y T ^a   Chen, D Y ^a,e   Lan, J L ^a,e   Lin, C C ^a,e  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d Yeastern Biotech Co   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

DNA vaccine; Forkhead box O3 (Foxo3); HER 2 neu; short hairpin RNA (shRNA); tumor

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; PLASMID VECTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG POTENCY; FEMALE; GENE GUN IMMUNIZATION; GENE SILENCING; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; RNA INTERFERENCE; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGEN-PRESENTING CELLS; BIOLISTICS; CANCER VACCINES; CELL LINE; CERCOPITHECUS AETHIOPS; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; GENES, ERBB-2; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS; VACCINES, DNA;

MUS;

EID: 79953800932     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.146     Document Type: Article

References (52)

1. Cavallo F, Offringa R, Van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213. (Pubitemid 43765801)
2. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 2003; 31: 232-242. (Pubitemid 37162796)
3. + T cells after gene gun immunization. J Exp Med 1998; 188: 1075-1082. (Pubitemid 28443331)
4. Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 2006; 17: 1062-1076. (Pubitemid 44749709)
5. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65: 309-316. (Pubitemid 40070823)
6. Huang B, Mao CP, Peng S, Hung CF, Wu TC. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008; 19: 763-773.
7. Dharmapuri S, Aurisicchio L, Biondo A, Welsh N, Ciliberto G, La Monica N. Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model. Hum Gene Ther 2009; 20: 589-597.
8. Singh A, Nie H, Ghosn B, Qin H, Kwak LW, Roy K. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther 2008; 16: 2011-2021.
9. Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 2009; 15: 641-649.
10. Peng SL. Immune regulation by Foxo transcription factors. Autoimmunity 2007; 40: 462-469. (Pubitemid 47343358)
11. Hedrick SM. The cunning little vixen: Foxo and the cycle of life and death. Nat Immunol 2009; 10: 1057-1063.
12. Maiese K, Chong ZZ, Shang YC, Hou J. A 'FOXO' in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009; 29: 395-418.
13. Su H, Bidere N, Lenardo M. Another fork in the road: Foxo3a regulates NF-kappaB activation. Immunity 2004; 21: 133-134. (Pubitemid 39094042)
14. Lin L, Hron JD, Peng SL. Regulation of NF-kappaB, Th activation, and autoinflamma-tion by the forkhead transcription factor Foxo3a. Immunity 2004; 21: 203-213. (Pubitemid 39094050)
15. Pandiyan P, Gärtner D, Soezeri O, Radbruch A, Schulze-Osthoff K, Brunner-Weinzierl MC. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med 2004; 199: 831-842. (Pubitemid 38375203)
16. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200: 1051-1062. (Pubitemid 39431129)
17. Dejean AS, Beisner DR, Ch'en IL, Kerdiles YM, Babour A, Arden KC et al. Transcription factor Foxo 3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009; 10: 504-513.
18. Pannellini T, Forni G, Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Dis 2004; 20: 33-42. (Pubitemid 39600444)
19. Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005; 65: 1071-1078. (Pubitemid 40216470)
20. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64: 2858-2864. (Pubitemid 38500626)
21. Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009; 182: 5873-5881.
22. Lin CC, Chou CW, Shiau AL, Tu CF, Ko TM, Chen YL et al. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 2004; 10: 290-301.
23. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111: 1161-1170. (Pubitemid 36519933)
24. Rohrbach F, Weth R, Kursar M, Sloots A, Mittrücker HW, Wels WS. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol 2005; 174: 5481-5489. (Pubitemid 40593188)
25. Dienz O, Rincon M. The effects of IL-6 on CD4T cell responses. Clin Immunol 2009; 13: 27-33.
26. Rochman I, Paul WE, Ben-Sasson SZ. IL-6 increases primed cell expansion and survival. J Immunol 2005; 174: 4761-4767.
27. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002; 70: 498-505. (Pubitemid 36194315)
28. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007; 28: 297-321. (Pubitemid 46984829)
29. Dharmapuri S, Aurisicchio L, Biondo A, Welsh N, Ciliberto G, La Monica N. Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model. Hum Gene Ther 2009; 20: 589-597.
30. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003; 112: 109-117. (Pubitemid 38056382)
31. Zhang L, Yi H, Xia XP, Zhao Y. Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance. Autoimmunity 2006; 39: 269-276. (Pubitemid 44203503)
32. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793. (Pubitemid 26372655)
33. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985; 41: 697-706.
34. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742. (Pubitemid 27458961)
35. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996; 98: 70-77. (Pubitemid 26243822)
36. Steitz J, Brück J, Lenz J, Knop J, Tüting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001; 61: 8643-8646. (Pubitemid 34013869)
37. Lai MD, Yen MC, Lin CM, Tu CF, Wang CC, Lin PS et al. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genet Vaccines Ther 2009; 7: 2.
38. Lin CC, Yen MC, Lin CM, Huang SS, Yang HJ, Chow NH et al. Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 2008; 10: 679-689.
39. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplan-table carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 5133-5142.
40. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001; 61: 880-883. (Pubitemid 32174395)
41. Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007; 13: 6195-6203. (Pubitemid 350075081)
42. Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 2003; 63: 2518-2525. (Pubitemid 36605192)
43. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 2009; 15: 1575-1584.
44. Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U et al. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res 2008; 14: 6933-6943.
45. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993; 177: 1127-1134. (Pubitemid 23097401)
46. Lu TJ, Lai WY, Huang CY, Hsieh WJ, Yu JS, Hsieh YJ et al. Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and proteintyrosine phosphatase-PEST. J Biol Chem 2006; 281: 38405-38417.
47. Chu CL, Lowell CA. The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol 2005; 175: 2880-2889. (Pubitemid 41170505)
48. Tomiyama-Hanayama M, Rakugi H, Kohara M, Mima T, Adachi Y, Ohishi M et al. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 2009; 297: F679-F684.
49. Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002; 20: 304-311. (Pubitemid 36299051)
50. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008; 36: W509-W512.
51. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219. (Pubitemid 30099526)
52. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003; 4: 410-415. (Pubitemid 36592430)